May 09, 2019 12:06 JST

Source: Eisai

Eisai Commences Venture Investment Business Aimed at Accelerating Innovation in Drug Creation and Establishment of Ecosystem Platform

TOKYO, May 09, 2019 - (JCN Newswire) - Eisai Co., Ltd. announced today that the company has commenced a venture investment business for the purpose of excavating innovative technologies, supporting venture businesses with such technologies, and partnering with those businesses in the future, so as to accelerate innovation in drug creation as well as the establishment of ecosystem platform.

In line with its medium-term business plan EWAY2025, Eisai is conducting research and development activities through various approaches at Eisai's global drug creation sites, in order to create next-generation drugs mainly in the "neurology" and "oncology" areas defined as Eisai's therapeutic areas of focus. Eisai is aiming to deliver novel benefits to patients and their families, by establishing the "Platform" via actively utilizing external big data and genomic data in addition to Eisai's own experience, know-how, and clinical data, as well as by building the "Ecosystem" via collaborating with partners such as other pharmaceutical companies, governments, medical organizations, care facilities, diagnostic developing companies, IT companies and insurance companies. As the first step, Eisai is proceeding with the efforts for the establishment of the dementia ecosystem.

In this investment business, Eisai invests approximately 3 billion yen per year for five years within the framework of 15 billion yen in total in venture businesses which can contribute to patient benefits that Eisai aims for by have synergy with Eisai's researches in the neurology and oncology areas, as well as having innovative digital technologies supporting the establishment of the ecosystem platform.

While Eisai begins this investment business in Tokyo to lead healthcare-related ecosystems in Japan, the company also plans to set up satellite offices in Cambridge, Massachusetts and San Francisco, California, two of the major clusters for digital health and biotech ventures in the United States, thus globally expanding investment areas.

Building on its long-cultivated capacity of global drug discovery and its network with local communities, Eisai is committed to utilizing this investment business to accelerate innovation in drug creation in agile cooperation with academia, drug discovery ventures, IT ventures, and strengthen the construction of the ecosystem platform as it seeks to further contribute to increasing the benefits provided to consumers, patients and their families in the world.

About Eisai
Eisai Co., Ltd. defines our corporate mission as "giving first thought to patients and their families and to increasing the benefits health care provides," which we call our human health care (hhc) philosophy. With approximately 10,000 employees working across our global network of R&D facilities, manufacturing sites and marketing subsidiaries, we strive to realize our hhc philosophy by delivering innovative products to address unmet medical needs, with a particular focus in our strategic areas of Neurology and Oncology. As a global pharmaceutical company, our mission extends to patients around the world through working with key stakeholders to improve access to medicines in developing and emerging countries.

For more information about Eisai Co., Ltd., please visit

Public Relations Department,
Eisai Co., Ltd.
Source: Eisai
Sectors: BioTech

Copyright ©2020 JCN Newswire. All rights reserved. A division of Japan Corporate News Network.

Related Press Release

Eisai to Launch New Selbelle Premium Tablets and New Selbelle Premium Fine Granules
May 18 2020 12:33 JST
Eisai to Present Data on Oncology Pipeline and Products at ASCO20 Annual Meeting
May 14 2020 08:22 JST
Eisai Selected as Most Honored Company and the First Place of the Sector in "The All-Japan Executive Team (Best IR Company Ranking)" by Institutional Investor Magazine
April 27 2020 16:26 JST
Eisai and Seikagaku Enter into Agreement for the Co-development and Marketing Alliance of SI-613, a Treatment of Osteoarthritis, in China
April 01 2020 15:23 JST
Eisai Submits Marketing Authorization Application in Japan for Anticancer Agent Denileukin Diftitox (Genetic Recombinant)
March 26 2020 16:01 JST
Eisai's Discovery Research on Multikinase Inhibitor Lenvatinib Honored with PSJ Award for Drug Research and Development '20
March 25 2020 08:38 JST
Eisai to Launch Digital Tool "NouknowTM" in Japan for Regular Self-Assessment of Brain Performance (Brain Health)
March 23 2020 10:53 JST
Eisai: All-case Surveillance Condition for Approval of "Actonel 17.5 mg tablets" for Treatment of Paget's Disease of Bone Cleared in Japan
March 19 2020 14:15 JST
Eisai and FUJI YAKUHIN Conclude License Agreement Concerning the Development and Distribution of Dotinurad, a Treatment for Hyperuricemia and Gout, in China
February 25 2020 08:10 JST
Eisai Receives the President's Award of the Japan Techno-Economics Society at the 8th Technology Management and Innovation Awards
February 21 2020 16:55 JST
More Press release >>

Latest Press Release

More Latest Release >>